SEC Form 4 · accession 0001209191-16-142628

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Sep 21, 2016

Accepted (ET)

Sep 23, 2016 · 4:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Sep 21, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Sep 21, 2016	S	1,900	$89.73	D	272,825	D
Common Stock^F2,F4	Sep 21, 2016	S	2,500	$90.77	D	270,325	D
Common Stock^F2,F5	Sep 21, 2016	S	1,900	$91.82	D	268,425	D
Common Stock^F2,F6	Sep 21, 2016	S	200	$92.31	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401k
Common Stock	holding	—	—		—	78,200	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$36.30	Sep 21, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	105,500	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $89.73 (range $89.21 to $90.20).
F4Open market sales reported on this line occurred at a weighted average price of $90.77 (range $90.25 to $91.23).
F5Open market sales reported on this line occurred at a weighted average price of $91.82 (range $91.27 to $92.21).
F6Open market sales reported on this line occurred at a weighted average price of $92.31 (range $92.27 to $92.35).
F7Fully vested.